152 related articles for article (PubMed ID: 18202455)
1. Docking mode of delvardine and its analogues into the p66 domain of HIV-1 reverse transcriptase: screening using molecular mechanics-generalized born/surface area and absorption, distribution, metabolism and excretion properties.
Sengupta D; Verma D; Naik PK
J Biosci; 2007 Dec; 32(7):1307-16. PubMed ID: 18202455
[TBL] [Abstract][Full Text] [Related]
2. Docking-MM-GB/SA and ADME screening of HIV-1 NNRTI inhibitor: nevirapine and its analogues.
Sengupta D; Verma D; Naik PK
In Silico Biol; 2008; 8(3-4):275-89. PubMed ID: 19032162
[TBL] [Abstract][Full Text] [Related]
3. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
4. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
5. Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
Wang J; Kang X; Kuntz ID; Kollman PA
J Med Chem; 2005 Apr; 48(7):2432-44. PubMed ID: 15801834
[TBL] [Abstract][Full Text] [Related]
6. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets.
Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA
Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000
[TBL] [Abstract][Full Text] [Related]
7. From docking false-positive to active anti-HIV agent.
Barreiro G; Kim JT; Guimarães CR; Bailey CM; Domaoal RA; Wang L; Anderson KS; Jorgensen WL
J Med Chem; 2007 Nov; 50(22):5324-9. PubMed ID: 17918923
[TBL] [Abstract][Full Text] [Related]
8. Rational approaches for the design of effective human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitors.
Ribone SR; Quevedo MA; Madrid M; Briñón MC
J Chem Inf Model; 2011 Jan; 51(1):130-8. PubMed ID: 21133347
[TBL] [Abstract][Full Text] [Related]
9. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
10. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
11. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
[TBL] [Abstract][Full Text] [Related]
12. Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoring.
Barreiro G; Guimarães CR; Tubert-Brohman I; Lyons TM; Tirado-Rives J; Jorgensen WL
J Chem Inf Model; 2007; 47(6):2416-28. PubMed ID: 17949071
[TBL] [Abstract][Full Text] [Related]
13. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
14. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
Sluis-Cremer N; Temiz NA; Bahar I
Curr HIV Res; 2004 Oct; 2(4):323-32. PubMed ID: 15544453
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, HIV-1 RT inhibitory, antibacterial, antifungal and binding mode studies of some novel N-substituted 5-benzylidine-2,4-thiazolidinediones.
Bahare RS; Ganguly S; Choowongkomon K; Seetaha S
Daru; 2015 Jan; 23(1):6. PubMed ID: 25617150
[TBL] [Abstract][Full Text] [Related]
16. Computer-aided identification of lead compounds as Staphylococcal epidermidis FtsZ inhibitors using molecular docking, virtual screening, DFT analysis, and molecular dynamic simulation.
Tripathy S; Sahu SK; Azam MA; Jupudi S
J Mol Model; 2019 Nov; 25(12):360. PubMed ID: 31773394
[TBL] [Abstract][Full Text] [Related]
17. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations.
Rodríguez-Barrios F; Gago F
J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase.
Temiz NA; Bahar I
Proteins; 2002 Oct; 49(1):61-70. PubMed ID: 12211016
[TBL] [Abstract][Full Text] [Related]
19. Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase.
Medina-Franco JL; Rodríguez-Morales S; Juárez-Gordiano C; Hernández-Campos A; Jiménez-Barbero J; Castillo R
Bioorg Med Chem; 2004 Dec; 12(23):6085-95. PubMed ID: 15519154
[TBL] [Abstract][Full Text] [Related]
20. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches.
Cutinho PF; Roy J; Anand A; Cheluvaraj R; Murahari M; Chimatapu HSV
J Biomol Struct Dyn; 2020 Apr; 38(6):1626-1648. PubMed ID: 31046644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
